Genomma Lab Intl Sab Ord (GNMLF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen. Thank you for joining Genoma Lab's second quarter 2026 earnings conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. As a reminder, this meeting is being recorded and will be available for replay from the investor relations section of Genoma's website following the call. I'll now turn the call over to Christianne Ibáñez, Genoma's Head of Investor Relations. Please go ahead. Thank you and welcome everyone. On today's call are Marco Sparvieri, Chief Executive Officer, and Antonio Zamora, Chief Financial Officer. Before we get started, I'd like to remind you that the remarks today will include forward-looking statements such as the company's financial guidance and expectations, including long-term objectives and forecasts, as well as expectations regarding Genoma's business, products, strategies, demand, and markets. These statements are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today, and the company undertakes no obligation to update them as a result of new information or future events. Now, let me turn the call over to Mr. Marco Sparvieri. Please go ahead. Thank you, Chris, and thank you everyone for joining our second quarter 2026 earning call. Let me open with the quarter highlights. First, the quarter came in line with our expectations and our growth initiatives are gaining traction. Mexico delivered a sequential sales improvement as we maintained or grew market share across all our businesses units, despite full market category contraction. The consumption environment remains challenging. Full market category contractions in Mexico continue to wait on the compan...